Amyris Biotechnologies Secures Investment from Temasek Holdings

EMERYVILLE, Calif.--()--Amyris Biotechnologies, Inc. announced today that Temasek Holdings has invested $47.8 million into the company. Amyris intends to use these funds to support commercial plant design and construction activities as well as ongoing operations in the U.S. and Brazil.

“We are privileged to welcome Temasek as a significant investor, and appreciate having them join us as we look to commercialize and scale our renewable fuels and chemicals,” said John Melo, chief executive officer of Amyris.

Amyris has secured $244 million in private funding since inception in 2003, including funding directly into Amyris Biotechnologies and into its subsidiary, Amyris Brasil S.A. Other Amyris investors include Kleiner Perkins Caufield & Byers, Khosla Ventures, TPG Biotechnology, Votorantim Novos Negocios, Advanced Equities Inc., DAG Ventures, Grupo Cornélio Brennand, Naxos U.K., The Westly Group, and Stratus Group.

About Amyris

Amyris is an integrated, renewable products company striving to help the world reduce its carbon footprint through the production and use of renewable chemicals and transportation fuels. Amyris’ strategy is to combine technology, production and distribution with the goal of commercializing and scaling products effectively while participating across the supply chain. Amyris applies synthetic biology to create a broad range of products, and is combining this technology with growing scale up and production capabilities through its subsidiary, Amyris Brasil S.A. Amyris is also building distribution capabilities, including through its U.S. subsidiary Amyris Fuels, LLC. More information about Amyris and its subsidiaries is available at www.amyris.com or www.amyrisbrasil.com.

Contacts

Amyris Biotechnologies, Inc.
Erin Kinsella, 510-597-4713
kinsella@amyris.com

Sharing

Contacts

Amyris Biotechnologies, Inc.
Erin Kinsella, 510-597-4713
kinsella@amyris.com